LB Pharmaceuticals Inc
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Revenue | — | — | — |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | — | $16.7M | $51.2M |
| SG&A Expense | — | $13.7M | $13.7M |
| Operating Income | — | $-25.2M | $-63.1M |
| Operating Margin | — | — | — |
| Interest Expense | — | — | — |
| Pretax Income | — | $-25.2M | $-63.1M |
| Income Tax Expense | — | $1.0K | $1.0K |
| Net Income | — | $-25.2M | $-63.1M |
| Net Margin | — | — | — |
| EPS (Basic) | — | $-3.13 | $-8.01 |
| EPS (Diluted) | — | $-3.13 | $-8.01 |
| Shares Outstanding (Basic) | 28.7M | 8.0M | 7.9M |
| Shares Outstanding (Diluted) | 28.7M | 8.0M | 7.9M |
| Dividends Per Share | — | — | — |